 profits slide profits fell research costs rose sales flagged firm profits rupees 915,000 months sales fell rupees built reputation producing generic versions pharmaceutical products competition intensified firm company short new product launches recent exclusive marketing rights generic version famous maker lost key court case march banning selling version popular hypertension drug research development new drugs continuing apace r spending rising rupees key cause decrease profits alongside fall sales patents number products run near future representing opportunity shares listed new generics manufacturers sales generics business fell 8.6 rupees staple firm business sale ingredients drugs performed poorly sales previous rupees face strong competition home competitors gathering strength face heavy competitive pressures